The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
This CME/CEU/CPE symposium will focus on risk of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) & associated liver fibrosis in people with T2 diabetes, and includes summaries of ADA and other Guidelines on screening, diagnosis, current treatment practice, as well as presentation of novel Phase III data. Clinical Cases will illustrate management of patients with mild/moderate/severe NASH, and your queries will be addressed during a robust Q&A session.
You must be logged in and own this session in order to
post comments.